<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Fertil Steril</journal-id><journal-id journal-id-type="iso-abbrev">Fertil Steril</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Fertility and sterility</journal-title></journal-title-group><issn pub-type="ppub">0015-0282</issn><issn pub-type="epub">1556-5653</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11839334</article-id><article-id pub-id-type="pmcid-ver">PMC11839334.1</article-id><article-id pub-id-type="pmcaid">11839334</article-id><article-id pub-id-type="pmcaiid">11839334</article-id><article-id pub-id-type="manuscript-id">NIHMS2028453</article-id><article-id pub-id-type="pmid">39306190</article-id><article-id pub-id-type="doi">10.1016/j.fertnstert.2024.09.024</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS2028453</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA2028453</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Contraception Use and Changes in Young Women with Newly Diagnosed Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Tesch</surname><given-names initials="ME">Megan E.</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sorouri</surname><given-names initials="K">Kimia</given-names></name><degrees>MD, MPH</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A4" ref-type="aff">d</xref><xref rid="FN1" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zheng</surname><given-names initials="Y">Yue</given-names></name><degrees>MSc</degrees><xref rid="A5" ref-type="aff">e</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names initials="SM">Shoshana M.</given-names></name><degrees>ScD, MPH</degrees><xref rid="A6" ref-type="aff">f</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ruddy</surname><given-names initials="KJ">Kathryn J.</given-names></name><degrees>MD, MPH</degrees><xref rid="A7" ref-type="aff">g</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Emmons</surname><given-names initials="KM">Karen M.</given-names></name><degrees>PhD</degrees><xref rid="A8" ref-type="aff">h</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Caryn Dutton</surname><given-names initials="M">M.</given-names></name><degrees>MD, MS</degrees><xref rid="A3" ref-type="aff">c</xref><xref rid="A9" ref-type="aff">i</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Partridge</surname><given-names initials="AH">Ann H.</given-names></name><degrees>MD, MPH</degrees><xref rid="A1" ref-type="aff">a</xref><xref rid="A2" ref-type="aff">b</xref><xref rid="A3" ref-type="aff">c</xref><xref rid="CR1" ref-type="corresp">**</xref></contrib></contrib-group><aff id="A1"><label>a</label>Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA</aff><aff id="A2"><label>b</label>Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA</aff><aff id="A3"><label>c</label>Harvard Medical School, Boston, MA, USA</aff><aff id="A4"><label>d</label>University of Alberta, Edmonton, AB, Canada</aff><aff id="A5"><label>e</label>Biostatistics Department, Dana-Farber Cancer Institute, Boston, MA, USA</aff><aff id="A6"><label>f</label>Weill Cornell Medicine, New York, NY, USA</aff><aff id="A7"><label>g</label>Mayo Clinic, Rochester, MN, USA</aff><aff id="A8"><label>h</label>Harvard T. H. Chan School of Public Health, Boston, MA, USA</aff><aff id="A9"><label>i</label>Brigham and Women&#8217;s Hospital, Boston, MA, USA</aff><author-notes><fn fn-type="equal" id="FN1"><label>*</label><p id="P1">These authors contributed equally.</p></fn><fn fn-type="con" id="FN2"><p id="P2">Authors&#8217; Contributions:</p><p id="P3"><bold>Conceptualization:</bold> M.E.T., K.S., S.M.R, K.J.R., K.M.E., M.C.D, A.H.P. <bold>Methodology:</bold> M.E.T., K.S., M.C.D., A.H.P. <bold>Formal analysis:</bold> M.E.T., K.S, Y.Z. <bold>Writing &#8211; original draft:</bold> M.E.T., K.S. <bold>Writing &#8211; review and editing:</bold> M.E.T., K.S., S.M.R, K.J.R., K.M.E., M.C.D, A.H.P.</p></fn><corresp id="CR1"><label>**</label><bold>Corresponding Author:</bold> Dr. Ann H. Partridge, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, USA 02115, <email>ann_partridge@dfci.harvard.edu</email></corresp><fn fn-type="COI-statement" id="FN4"><p id="P42"><bold>Disclosure Statement:</bold> A.H.P., K.J.R., and M.C.D. receive royalties from Wolters Kluwer from Wolters Kluwer (UpToDate). A.H.P. has received research support from Novartis. All other authors have no conflicts to report.</p></fn></author-notes><pub-date pub-type="ppub"><month>3</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>19</day><month>9</month><year>2024</year></pub-date><volume>123</volume><issue>3</issue><issue-id pub-id-type="pmc-issue-id">482564</issue-id><fpage>488</fpage><lpage>498</lpage><pub-history><event event-type="nihms-submitted"><date><day>03</day><month>11</month><year>2024</year></date></event><event event-type="pmc-release"><date><day>01</day><month>03</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-23 11:25:28.793"><day>23</day><month>02</month><year>2025</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-2028453.pdf"/><abstract id="ABS1"><sec id="S1"><title>Objective:</title><p id="P4">To evaluate contraception use and change among young women with early breast cancer.</p></sec><sec id="S2"><title>Design:</title><p id="P5">Secondary analysis of a cluster randomized trial.</p></sec><sec id="S3"><title>Subjects:</title><p id="P6">Patients with newly diagnosed breast cancer age &#8804;45 years enrolled from 54 U.S. oncology practices.</p></sec><sec id="S4"><title>Exposure:</title><p id="P7">Sites were randomized to the Young Women&#8217;s Intervention, an educational intervention for young women with newly diagnosed breast cancer and their oncologists addressing issues specific to this population, including contraception, or a contact-time control Physical Activity Intervention. Participants completed surveys in follow-up, including a 3-month survey regarding contraceptive practices before and after diagnosis.</p></sec><sec id="S5"><title>Main Outcome Measures:</title><p id="P8">Outcomes of interest included young women&#8217;s contraceptive use and methods before breast cancer diagnosis and 3 months after study enrollment. Logistic regression models assessed factors associated with use of less than highly effective contraceptive methods categorized according to WHO effectiveness tiers and changes in contraceptive methods.</p></sec><sec id="S6"><title>Results:</title><p id="P9">Of 312 women included, 258 (83%) reported contraceptive use before breast cancer diagnosis, and 275 (88%) reported contraceptive use after diagnosis. Use of highly effective methods (e.g, vasectomy, non-hormonal intrauterine devices) increased from 39% before diagnosis to 52% after diagnosis. Use of moderately effective methods (e.g., hormonal methods), decreased from 22% before diagnosis to 3% after diagnosis. Use of less effective methods (e.g, condoms, withdrawal) increased from 22% before diagnosis to 34% after diagnosis. On multivariable analysis, factors associated with using less than highly effective contraception after diagnosis included desire for additional children (odds ratio (OR) 6.33, 95% confidence interval (CI) 3.76&#8211;10.66, p&lt;0.001) and discussing contraception with a provider (OR 1.96, 95% CI 1.12&#8211;3.40, p=0.018). After breast cancer diagnosis, 207 patients (66%) reported no change in contraceptive methods. On multivariable analysis, factors associated with contraceptive method change after diagnosis included age &lt;35 years (OR 2.96. 95% CI 1.57&#8211;5.58, p-value &lt;0.001) and provider discussion (OR 3.59, 95% CI 1.91&#8211;6.78, p&lt;0.001). There was no association in either analysis with study arm.</p></sec><sec id="S7"><title>Conclusion:</title><p id="P10">Although most patients used contraception after breast cancer diagnosis, nearly half reported using less than highly effective contraceptive methods with higher failure rates, highlighting the need for early and improved contraceptive counseling for young women with breast cancer.</p></sec></abstract><abstract id="ABS2" abstract-type="summary"><title>Capsule:</title><p id="P11">Use of contraceptive methods with high failure rates was frequent among young women following a breast cancer diagnosis, highlighting the need for improved contraceptive counseling for this patient population.</p></abstract><kwd-group><kwd>breast cancer</kwd><kwd>contraception</kwd><kwd>adolescent and young adult cancer patients</kwd><kwd>premenopausal</kwd><kwd>contraceptive efficacy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-exception-type</meta-name><meta-value>EMBARGO</meta-value></custom-meta><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>4</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>no</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>